The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
Scott D. Kuduk - One of the best experts on this subject based on the ideXlab platform.
-
Bradykinin B1 antagonists: SAR studies in the 2,3-Diaminopyridine series.
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Scott D. Kuduk, Ronald K. Chang, Christina Ng, Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Kathy L Murphy, Richard W Ransom, Douglas J. Pettibone, Mark G. BockAbstract:SAR study of the biphenyl region of 2,3-Diaminopyridine bradykinin B 1 antagonists was investigated with non-aromatic carbo- and heterocyclic rings. A piperidine ring was found to be a good replacement for the proximal phenyl ring while replacement of the distal phenyl was optimal with a cyclohexyl group leading to a dramatic improvement in affinity for the B 1 receptor.
-
2 3 Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin b1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Dongmei Feng, Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Tanya Macneil, Cuyue TangAbstract:Abstract A novel class of 2,3-Diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure–activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
-
2 3 Diaminopyridine bradykinin b1 receptor antagonists
Journal of Medicinal Chemistry, 2004Co-Authors: Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Dongmei Feng, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Magnus Ivarsson, G MasonAbstract:Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-Diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.
Dongmei Feng - One of the best experts on this subject based on the ideXlab platform.
-
2 3 Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin b1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Dongmei Feng, Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Tanya Macneil, Cuyue TangAbstract:Abstract A novel class of 2,3-Diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure–activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
-
2 3 Diaminopyridine bradykinin b1 receptor antagonists
Journal of Medicinal Chemistry, 2004Co-Authors: Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Dongmei Feng, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Magnus Ivarsson, G MasonAbstract:Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-Diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.
Richard W Ransom - One of the best experts on this subject based on the ideXlab platform.
-
Bradykinin B1 antagonists: SAR studies in the 2,3-Diaminopyridine series.
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Scott D. Kuduk, Ronald K. Chang, Christina Ng, Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Kathy L Murphy, Richard W Ransom, Douglas J. Pettibone, Mark G. BockAbstract:SAR study of the biphenyl region of 2,3-Diaminopyridine bradykinin B 1 antagonists was investigated with non-aromatic carbo- and heterocyclic rings. A piperidine ring was found to be a good replacement for the proximal phenyl ring while replacement of the distal phenyl was optimal with a cyclohexyl group leading to a dramatic improvement in affinity for the B 1 receptor.
-
2 3 Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin b1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Dongmei Feng, Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Tanya Macneil, Cuyue TangAbstract:Abstract A novel class of 2,3-Diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure–activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
-
2 3 Diaminopyridine bradykinin b1 receptor antagonists
Journal of Medicinal Chemistry, 2004Co-Authors: Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Dongmei Feng, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Magnus Ivarsson, G MasonAbstract:Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-Diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.
Kathy L Murphy - One of the best experts on this subject based on the ideXlab platform.
-
Bradykinin B1 antagonists: SAR studies in the 2,3-Diaminopyridine series.
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Scott D. Kuduk, Ronald K. Chang, Christina Ng, Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Kathy L Murphy, Richard W Ransom, Douglas J. Pettibone, Mark G. BockAbstract:SAR study of the biphenyl region of 2,3-Diaminopyridine bradykinin B 1 antagonists was investigated with non-aromatic carbo- and heterocyclic rings. A piperidine ring was found to be a good replacement for the proximal phenyl ring while replacement of the distal phenyl was optimal with a cyclohexyl group leading to a dramatic improvement in affinity for the B 1 receptor.
-
2 3 Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin b1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Dongmei Feng, Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Tanya Macneil, Cuyue TangAbstract:Abstract A novel class of 2,3-Diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure–activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
-
2 3 Diaminopyridine bradykinin b1 receptor antagonists
Journal of Medicinal Chemistry, 2004Co-Authors: Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Dongmei Feng, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Magnus Ivarsson, G MasonAbstract:Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-Diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.
Christina Ng - One of the best experts on this subject based on the ideXlab platform.
-
Bradykinin B1 antagonists: SAR studies in the 2,3-Diaminopyridine series.
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Scott D. Kuduk, Ronald K. Chang, Christina Ng, Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Kathy L Murphy, Richard W Ransom, Douglas J. Pettibone, Mark G. BockAbstract:SAR study of the biphenyl region of 2,3-Diaminopyridine bradykinin B 1 antagonists was investigated with non-aromatic carbo- and heterocyclic rings. A piperidine ring was found to be a good replacement for the proximal phenyl ring while replacement of the distal phenyl was optimal with a cyclohexyl group leading to a dramatic improvement in affinity for the B 1 receptor.
-
2 3 Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin b1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2005Co-Authors: Dongmei Feng, Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Tanya Macneil, Cuyue TangAbstract:Abstract A novel class of 2,3-Diaminopyridine bradykinin B1 receptor antagonists is disclosed. Structure–activity relationship studies (SARs) that led to compounds with significantly improved potency and pharmacokinetic properties relative to the lead compound are described.
-
2 3 Diaminopyridine bradykinin b1 receptor antagonists
Journal of Medicinal Chemistry, 2004Co-Authors: Scott D. Kuduk, Christina Ng, Kathy L Murphy, Richard W Ransom, Dongmei Feng, Duane R Reiss, Raymond S L Chang, Charles M Harrell, Magnus Ivarsson, G MasonAbstract:Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-Diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.